Holdings Channel
Home Articles Latest Filings All Funds Stocks Being Bought Stocks Being Sold Insider Buying
Play Video: The Importance of Insider Buying


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
EPZM — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree EPZM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

EPZM — Performance
Epizyme insider buying image
The table below summarizes the most recent Epizyme insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Epizyme insider buys are important for investors to follow.
DateInsiderPriceAmount
3-26-2021
Insider Buy		 David M. Mott
Director		 $7.97
CAGR » 		$500,099.91
62,717 shares
11-11-2020
Insider Buy		 Carl Goldfischer
Director		 $12.07
CAGR » 		$60,350.00
5,000 shares
6-26-2020
Insider Buy		 David M. Mott
Director		 $16.03
CAGR » 		$994,164.57
62,019 shares
9-18-2017
Insider Buy		 David M. Mott
Director		 $15.25
CAGR » 		$3,050,000.00
200,000 shares
8-20-2015
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $16.51
CAGR » 		$33,020.00
2,000 shares
1-12-2016
Insider Buy		 Enterprise Associates 13 LP New
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 M. James Barrett
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Peter J. Barris
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Forest Baskett
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Patrick J. Kerins
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Krishna Kittu Kolluri
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 David M. Mott
Director and >10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Scott D. Sandell
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Ravi Viswanathan
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 Harry R. Weller
>10% Owner		 $9.00
CAGR » 		$9,999,999.00
1,111,111 shares
1-12-2016
Insider Buy		 BAY CITY CAPITAL LLC
>10% Owner		 $9.00
CAGR » 		$4,999,995.00
555,555 shares
1-12-2016
Insider Buy		 Carl Goldfischer
Director		 $9.00
CAGR » 		$4,999,995.00
555,555 shares
12-9-2015
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $14.69
CAGR » 		$14,690.00
1,000 shares
8-31-2015
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $17.00
CAGR » 		$8,874.00
522 shares
8-20-2015
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $16.51
CAGR » 		$33,020.00
2,000 shares
5-5-2015
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $16.36
CAGR » 		$13,084.40
800 shares
12-16-2014
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $17.63
CAGR » 		$7,052.00
400 shares
12-2-2014
Insider Buy		 Peter Tai-ching Ho
Chief Development Officer		 $21.17
CAGR » 		$21,168.00
1,000 shares
2-10-2014
Insider Buy		 Celgene European Investment Co LLC
>10% Owner		 $29.25
CAGR » 		$9,945,000.00
340,000 shares
11-15-2013
Insider Buy		 Enterprise Associates 13 LP New
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 M. James Barrett
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Peter J. Barris
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Forest Baskett
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Ryan D. Drant
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Patrick J. Kerins
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Krishna Kittu Kolluri
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 David M. Mott
Director and >10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Scott D. Sandell
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Ravi Viswanathan
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
11-15-2013
Insider Buy		 Harry R. Weller
>10% Owner		 $19.68
CAGR » 		$7,997,980.66
406,500 shares
6-5-2013
Insider Buy		 M. James Barrett
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Scott D. Sandell
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Peter J. Barris
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Forest Baskett
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Krishna Kittu Kolluri
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Ryan D. Drant
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Patrick J. Kerins
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Enterprise Associates 13 LP New
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 David M. Mott
Director and >10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Harry R. Weller
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Ravi Viswanathan
>10% Owner		 $15.00
CAGR » 		$6,000,000.00
400,000 shares
6-5-2013
Insider Buy		 Venture Fund I. L.P. Astellas
>10% Owner		 $15.00
CAGR » 		$229,995.00
15,333 shares
6-5-2013
Insider Buy		 Celgene European Investment Co LLC
>10% Owner		 $15.00
CAGR » 		$999,990.00
66,666 shares
6-5-2013
Insider Buy		 Amgen Ventures LLC
>10% Owner		 $15.00
CAGR » 		$249,990.00
16,666 shares

Also See: Institutional Holders of EPZM
Also See: SEC filings

EPZM Performance Since Insider Purchase
Below we present the annualized performance delivered by Epizyme stock since 3-26-2021 (the date of the most recent insider purchase). The performance of the investment from the time Epizyme insider buying occurred is the ultimate test of whether insiders were right about EPZM being a good buy.

Growth of $10,000.00
Without Dividends Reinvested
Start date: 03/29/2021
End date: 08/12/2022
Start price/share: $7.45
End price/share: $1.47
Dividends collected/share: $0.00
Total return: -80.27%
Average Annual Total Return: -69.35%
Starting investment: $10,000.00
Ending investment: $1,972.75
Years: 1.37

Epizyme Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Epizyme insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding EPZM

Epizyme Insider Buying | www.HoldingsChannel.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.